Exceptional Response to Crizotinib With Subsequent Response to Cabozantinib in Metastatic, ROS1-GOPC Fusion-Mutated Breast Cancer.
Sean R O'NeilGarrett A WeberDustin A DemingMark E BurkardParaic A KennyCraig S RichmondBenjamin M ParsonsPublished in: JCO precision oncology (2023)